Combined interferon alfa and lipsosmal-encapsulated all-trans retinoic acid, including preparation and use
AssigneeAronex Pharmaceuticals, Inc.
InventorDavid Nanus
Life of this patent
Estimating the term…
Abstract
Alfa interferon (α-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of α-interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from about 15 mg/m2 to about 90 mg/m2, or about 140 mg/m2, or about 300 mg/m2 or more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful.
Claims9
A method of inhibiting the growth of cancer cells comprising exposing cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein said retinoid is associated with lipid carrier particles.
A method of inhibiting the growth of cancer cells comprising
- exposing cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and further
- co-timely exposing of said cancerous cells to a therapeutically effective amount of a retinoid, wherein said retinoid is associated with lipid carrier particles.
A therapeutic treatment kit for the treatment of cancer comprising interferon, retinoid and instructional materials for the combined use of said retinoid and interferon.
Dependencies are inferred from the claim text.